Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

被引：3
|
作者：
Dumbrava, Ecaterina Elena
Shapiro, Geoffrey
Bendell, Johanna C.
Yap, Timothy A.
Jeselsohn, Rinath
Lepley, Denise M.
Hurley, Sabrina
Lin, Kevin K.
Liao, Michelle
Habeck, Jenn
Enke, Aaron
Hamilton, Erika P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] Clovis Oncol Inc, Boulder, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3102
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors
    Kopetz, S.
    Mita, M. M.
    Mok, I.
    Sankhala, K. K.
    Moseley, J.
    Sherman, B. M.
    Bradley, C. R.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.
    Samnotra, Vivek
    Shtessel, Veronica Moroz Luda
    Kuchimanchi, Mita
    Hanafin, Patrick
    Pannirselvam, Malar
    Bhaskar, Aishwarya
    Liu, Andrew
    Yuzugullu, Haluk
    Barve, Minal A.
    Sommerhalder, David
    Yap, Timothy A.
    Sanicola-Nadel, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
    Kummar, Shivaani
    Kinders, Robert
    Gutierrez, Martin E.
    Rubinstein, Larry
    Parchment, Ralph E.
    Phillips, Lawrence R.
    Ji, Jiuping
    Monks, Anne
    Low, Jennifer A.
    Chen, Alice
    Murgo, Anthony J.
    Collins, Jerry
    Steinberg, Seth M.
    Eliopoulos, Helen
    Giranda, Vincent L.
    Gordon, Gary
    Helman, Lee
    Wiltrout, Robert
    Tomaszewski, Joseph E.
    Doroshow, James H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2705 - 2711
  • [24] Phase 0 pharmacodynamic, pharmacokinetic study of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients with advanced malignancies
    Kummar, S.
    Gutierrez, M.
    Kinders, R.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L.
    Ji, J.
    Chen, A.
    Homeffer, Y.
    Juwara, L.
    Yancey, M.
    Murgo, A. J.
    Collins, J. M.
    Tomaszewski, J. E.
    Doroshow, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 20 - 20
  • [25] Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.
    Wysocki, Piotr Jan
    Lubas, Maciej Tadeusz
    Lobacz, Mateusz
    Kalinka-Warzocha, Ewa
    Tomczak, Piotr
    Kwiatek, Michal
    Lugowska, Iwona A.
    Smakal, Martin
    Chraniuk, Dominik
    Melichar, Bohuslav
    Markiewicz-Bialek, Beate
    Routhu, Kasi V.
    Barde, Prajak J.
    Nair, Ajit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors.
    Sharma, Sunil
    Kang, Yoon-Koo
    Weis, John R.
    Gilcrease, Glynn Weldon
    Davidson, Cynthia
    Kingsford, Rachel
    Collett, Joan
    Orgain, Nicole
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Park, Sook Ryun
    Yoo, Hee-Won
    Kim, Sung-Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-Ribose) polymerase (PARP)-1 and-2 inhibitor
    Zhang, Z-Y.
    Wang, X.
    Wang, J.
    Pentikis, H. S.
    Kansra, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors
    Samnotra, Vivek
    Moroz, Veronica
    Shtessel, Luda
    Kuchimanchi, Mita
    Hanafin, Patrick
    Pannirselvam, Malar
    Bhaskar, Aishwarya
    Liu, Andrew
    Yuzugullu, Haluk
    Barve, Minal
    Sommerhalder, David
    Yap, Timothy
    Sanicola-Nadel, Michele
    CANCER RESEARCH, 2024, 84 (07)
  • [29] Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
    Janku, Filip
    Birrer, Michael
    Richardson, Debra
    Chu, Christina
    Goel, Sanjay
    Su, Ying
    Matin, Bahar
    Kuida, Keisuke
    Ruiz-Soto, Rodrigo
    Hamilton, Erika Paige
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [30] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345